The IARC evaluation of Di(2-ethylhexyl)phthalate (DEHP): A flawed decision based on an untested hypothesis

International Journal of Occupational and Environmental Health

Volumn 8, Issue 3, 2002, Pages 284-286

  Melnick, Ronald L ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACYL COENZYME A OXIDASE; CARCINOGEN; CIPROFLOXACIN; CLOFIBRATE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PHTHALIC ACID BIS(2 ETHYLHEXYL) ESTER; RETINOID X RECEPTOR;

ANIMAL MODEL; APOPTOSIS; CANCER RESEARCH; CARCINOGENESIS; CELL PROLIFERATION; CHEMICAL CARCINOGENESIS; DECISION MAKING; ENZYME INDUCTION; HUMAN; HUMAN CELL; LIVER CANCER; LIVER CARCINOGENESIS; LIVER CELL; MOUSE; NONHUMAN; NOTE; PRIORITY JOURNAL;

EID: 0036656862     PISSN: 10773525     EISSN: None     Source Type: Journal    
DOI: 10.1179/oeh.2002.8.3.284     Document Type: Note

References (24)

1. Melnick RL. Is peroxisome proliferation an obligatory precursor step in the carcinogenicity of di(2-ethylhexyl)phthalate (DEHP)? Environ Health Perspect. 2001;109:437-42.
2. IARC. Di(2-ethylhexyl)phthalate. In: IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Vol. 77. Lyon, France: IARC, 2000:41-148.
3. Tomatis L. The IARC monographs program: changing attitudes towards public health. Int J Occup Environ Health. 2002;8:144-52.
4. Perrone CE, Shao L, Williams GM. Effect of rodent hepatocarcinogenic peroxisome proliferators on fatty acyl-CoA oxidase, DNA synthesis, and apoptosis in cultured human and rat hepatocytes. Toxicol Appl Pharmacol. 1998;150:277-86.
5. Doull J, Cattley R, Elcombe C, et al. A cancer risk assessment of di(2-ethylhexyl)phthalate: application of the new U.S. EPA risk assessment guidelines. Regul Toxicol Pharmacol. 1999;29:327-57.
6. Palmer CN, Hsu MH, Griffin KJ, Raucy JL, Johnson EF. Peroxisome proliferator activated receptor-alpha expression in human liver. Mol Pharmacol. 1998;53:14-22.
7. Tugwood JD, Aldridge TC, Lambe KG, Macdonald N, Woodyatt NJ. Peroxisome proliferator-activated receptors: structures and function. Ann NY Acad Sci. 1996;804:252-65.
8. Woodyatt NJ, Lambe KG, Myers KA, Tugwood JD, Roberts RA. The peroxisome proliferator (PP) response element upstream of the human acyl CoA oxidase gene is inactive among a sample human population: significance for species differences in response to PPs. Carcinogenesis. 1999;20:369-72.
9. Melnick RL. Peroxisome proliferators: response. Environ Health Perspect. 2001;109:A463-64.
10. Biegel LB, Hurtt ME, Frame SR, O'Connor JC, Cook JC. Mechanisms of extrahepatic tumor induction by peroxisome proliferators in male CD rats. Toxicol Sci. 2001;60:44-55.
11. Peters JM, Cattley RC, Gonzalez FJ. Role of PPAR alpha in the mechanism of action of the nongenotoxic carcinogen and peroxisome proliferator Wy-14,643. Carcinogenesis. 1997;18:2029-33.
12. National Toxicology Program (NTP). Carcinogenesis bioassay of di(2-ethylhexyl)phthalate (CAS No. 117-81-7) in F344 rats and B6C3F1 mice (feed study). NTP Technical Rpt 217. Bethesda, MD: National Institutes of Health, 1982.
13. Melnick RL, Huff J. Liver carcinogenesis is not a predicted outcome of chemically induced hepatocyte proliferation. Toxicol Ind Health. 1993;9:415-38.
14. Vu-Dac N, Schoonjans K, Kosykh V, et al. Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor. J Clin Invest. 1995;96:741-50.
15. Lawrence JW, Li Y, Chen S, et al. Differential gene regulation in human versus rodent hepatocytes by peroxisome proliferator-activated receptor (PPAR)α. J Biol Chem. 2001;276:31521-7.
16. Hsu MH, Savas U, Griffin KJ, Johnson EF. Identification of peroxisome proliferator-responsive human genes by elevated expression of peroxisome proliferator-activated receptor) α in HepG2 cells. J Biol Chem. 2001;276:27950-8.
17. Parzefall W, Berger W, Kainzbauer E, Teufelhofer O, Schulte-Hermann R, Thurman RG. Peroxisome proliferators do not increase DNA synthesis in purified rat hepatocytes. Carcinogenesis. 2001;22:519-23.
18. Hasmall S, James N, Hedley K, Olsen K, Roberts R. Mouse hepatocyte response to peroxisome proliferators: dependency on hepatic nonparenchymal cells and peroxisome proliferator activated receptor α (PPARα). Arch Toxicol. 2001;75:357-61.
19. Peters JM, Rusyn I, Rose ML, Gonzalez FJ, Thurman RG. Peroxisome proliferator-activated receptor (is restricted to hepatic parenchymal cells, not Kupffer cells: implications for the mechanism of action of peroxisome proliferators in hepatocarcinogenesis. Carcinogenesis. 2000;21:823-6.
20. Rusyn I, Yamashina S, Segal BH, et al. Oxidants from nicotinamide adenine dinucleotide phosphate oxidase are involved in triggering cell proliferation in the liver due to peroxisome proliferators. Cancer Res. 2000;60:4798-803.
21. Rusyn I, Kadiiska MB, Dikalova A, et al. Phthalates rapidly increase production of reactive oxygen species in vivo: role of Kupffer cells. Mol Pharmacol. 2001;59:744-50.
22. Gonzalez FJ. Recent update on the PPAR alpha-null mouse. Biochimie. 1997;79:139-44.
23. Peters JM, Hennuyer N, Staels B, et al. Alterations in lipoprotein metabolism in peroxisome proliferator-activated receptor alpha-deficient mice. J Biol Chem. 1997;272:27307-12.
24. Juge-Aubry CE, Gorla-Bajszczak A, Pernin A, et al. Peroxisome proliferator-activated receptor mediates cross-talk with thyroid hormone receptor by competition for retinoid X receptor. Possible role of a leucine zipper-like heptad repeat. J Biol Chem. 1995;270:18117-22.